Cannabis use was associated with substantially higher mortality, cardiovascular, and renal risk among patients with T2DM initiating GLP-1 RAs, with a dose-response pattern. Clinicians should inquire about cannabis use when prescribing GLP-1 RAs.
Cannabis use and cardiovascular, renal, and mortality outcomes in patients with type 2 diabetes receiving GLP-1 receptor agonists: A propensity score-matched cohort study